Pathophysiology - Donor's Deadly Attack
- Mechanism: Immunocompetent donor T-cells from the graft recognize the recipient's tissues as foreign, as the host is too immunocompromised to reject the graft.
- Key Players: Donor CD4+ and CD8+ T-cells react to the host's disparate Major Histocompatibility Complex (MHC) antigens.
- Cascade: This triggers a massive inflammatory response, often called a "cytokine storm," leading to widespread tissue damage.

⭐ Graft-versus-Leukemia (GVL) Effect: A beneficial "side effect" where donor T-cells also eliminate residual host cancer cells, particularly in hematopoietic stem cell transplants for leukemia.
- Mnemonic (📌): Major targets are Skin, Liver, GI tract ("Some Lethal Grafts").
Clinical Presentation - Acute vs. Chronic Clash
| Feature | Acute GVHD | Chronic GVHD |
|---|---|---|
| Onset | Typically < 100 days post-transplant | Typically > 100 days post-transplant |
| Mechanism | Donor CD8+ T-cells attack host epithelial cells | Donor CD4+ T-cells & B-cells cause autoimmune, fibrotic process |
| Skin | Maculopapular rash, erythema, bullae (may resemble SJS/TEN) | Poikiloderma, scleroderma-like changes, lichen planus-like lesions |
| GI Tract | Profuse, watery/bloody diarrhea; nausea, vomiting; abdominal pain | Esophageal webs/strictures, malabsorption, weight loss |
| Liver | Jaundice, ↑ conjugated bilirubin & alkaline phosphatase | Cholestatic jaundice, potentially progressing to cirrhosis |
| Other | - | Sicca syndrome (dry eyes/mouth), bronchiolitis obliterans, myositis |
⭐ Chronic GVHD is a major cause of late, non-relapse mortality following allogeneic transplant. It can arise de novo without any preceding acute GVHD.
Diagnosis & Prevention - Taming the Treachery
- Diagnosis: Primarily clinical (maculopapular rash, diarrhea, ↑LFTs).
- Biopsy is definitive: Shows lymphocytic infiltrate & apoptosis in skin, gut, or liver.
- Prevention: The cornerstone of management.
- HLA matching of donor and recipient is paramount.
- Immunosuppressive prophylaxis is standard.
- Calcineurin inhibitors (Cyclosporine, Tacrolimus)
- Methotrexate
⭐ Biopsy of affected organs (skin, gut, liver) is the gold standard for diagnosis, revealing lymphocytic infiltration and apoptosis, which confirms the T-cell mediated assault.
High‑Yield Points - ⚡ Biggest Takeaways
- In GVHD, transplanted donor T-cells attack recipient tissues, primarily after allogeneic bone marrow transplants.
- Key targets are the skin (diffuse maculopapular rash), liver (jaundice, ↑ LFTs), and GI tract (profuse diarrhea).
- The mechanism involves donor T-cells recognizing host MHC antigens as foreign.
- Acute GVHD develops <100 days post-transplant; chronic GVHD develops >100 days.
- Prophylaxis and treatment rely on immunosuppressive drugs like corticosteroids and cyclosporine.
- A beneficial graft-versus-leukemia effect may also occur in cancer patients.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app